Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate
Sayed, A., AK, M., Yousef, Z., Sayed, S. (2024). Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate. EKB Journal Management System, 7(1), 646-662. doi: 10.21608/svuijm.2023.229859.1650
Ali Abdel Rahman Sayed; Mohammed AK; Zahraa Abo Elmajd Yousef; Shamardan Ezz-Eldin Sayed. "Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate". EKB Journal Management System, 7, 1, 2024, 646-662. doi: 10.21608/svuijm.2023.229859.1650
Sayed, A., AK, M., Yousef, Z., Sayed, S. (2024). 'Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate', EKB Journal Management System, 7(1), pp. 646-662. doi: 10.21608/svuijm.2023.229859.1650
Sayed, A., AK, M., Yousef, Z., Sayed, S. Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate. EKB Journal Management System, 2024; 7(1): 646-662. doi: 10.21608/svuijm.2023.229859.1650

Non-Alcoholic Fatty Liver Disease in Cardiovascular Patients, Frequency, Risk Factors and Clinical Patterns in Qena Governorate

SVU-International Journal of Medical Sciences
Article 67, Volume 7, Issue 1, January 2024, Page 646-662  XML PDF (519.63 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2023.229859.1650
View on SCiNiTO View on SCiNiTO
Authors
Ali Abdel Rahman Sayed1; Mohammed AKorcid 2; Zahraa Abo Elmajd Yousef email 1; Shamardan Ezz-Eldin Sayedorcid 1
1Tropical Medicine and Gastroenterology Department, Faculty of Medicine, South Valley University, Qena, Egypt.
2Internal Medicine Department, Faculty of Medicine, South Valley University, Qena, Egypt.
Abstract
Background: Cardiovascular diseases (CVD) and liver disorders, like Non-Alcoholic Fatty Liver Disease (NAFLD), are major global health concerns, linked to significant morbidity and mortality.
Objectives: The study aimed to determine the prevalence of NAFLD in cardiac patients and identify risk factors contributing to its development.
Patients and methods: This cross-sectional research was conducted at Qena University Hospital, Egypt (April 2022–April 2023) on 100 cardiovascular patients. Assessments involved clinical, diagnostic, and laboratory methods, including liver function, lipid profile, abdominal ultrasonography, ECG, echocardiography, hepatitis testing, BMI, waist size, FibroScan, and NAFLD severity assessment.
Results: In a study of 24 adult NAFLD patients compared to 76 non-NAFLD cases, significant findings included NAFLD at S2 (62.5%) and S3 (37.5%) stages, all with F2 fibrosis. Significant gender distribution difference (p=0.014) with fewer males (33.3%). NAFLD patients were younger (60.08 vs. 63.92 years, p=0.0053) with higher BMI (32.62 vs. 29.66 kg/m2, p<0.001). Clinical characteristics showed significant increases in hypertension, diabetes, and other conditions in NAFLD (p<0.001). Cardiac differences included lower ejection fraction (p<0.001) and larger left atrial diameter (p=0.001) in NAFLD. Lipid profile variations included higher total cholesterol (p=0.034), LDL-C (p<0.001), and lower HDL-C (p<0.001) in NAFLD. Elevated liver function markers in NAFLD (p<0.001), with lower NFS score (p=0.012). Trends indicated a non-significant increase in cirrhosis prevalence in NAFLD (p=0.166), higher liver stiffness (p<0.001), and CAP score (p<0.001).
Conclusion: NAFLD significantly increase in Cardiac patients and significantly associated with factors like sex, age, BMI, chronic diseases, obesity, hyperlipidemia and heart diseases.
Keywords
NAFLD; Cardiovascular events; Metabolic Syndrome; Cardiometabolic Risk
Statistics
Article View: 53
PDF Download: 70